Related references
Note: Only part of the references are listed.GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins
Alain Beck et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
Development of BiosimilarsPharmacokinetic and Pharmacodynamic Considerations
Yow-Ming C. Wang et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2010)
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland
Alain Beck et al.
mAbs (2010)
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
Ezogelin Oflazoglu et al.
MABS (2010)
Antibodies to watch in 2010
Janice M. Reichert
MABS (2010)
Catumaxomab Clinical development and future directions
Rolf Linke et al.
MABS (2010)
Bioanalysis of recombinant proteins and antibodies by mass spectrometry
Eric Ezan et al.
ANALYST (2009)
Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody
Josef Vlasak et al.
ANALYTICAL BIOCHEMISTRY (2009)
Extending Mass Spectrometry Contribution to Therapeutic Monoclonal Antibody Lead Optimization: Characterization of Immune Complexes Using Noncovalent ESI-MS
Cedric Atmanene et al.
ANALYTICAL CHEMISTRY (2009)
Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis
R. Torres et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
P. Y. Muller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
Patrick Y. Muller et al.
CURRENT OPINION IN BIOTECHNOLOGY (2009)
Optimization of Fc-mediated effector functions of monoclonal antibodies
William R. Strohl
CURRENT OPINION IN BIOTECHNOLOGY (2009)
The effect of Fc glycan forms on human IgG2 antibody clearance in humans
Xiaoyu Chen et al.
GLYCOBIOLOGY (2009)
Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties IMPLICATIONS FOR MECHANISM OF ACTION IN VIVO
Adam Doern et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis
Roger Palframan et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
Pre- and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir
Wouter Koudstaal et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Structural characterization of a human Fc fragment engineered for extended serum half-life
Vaheh Oganesyan et al.
MOLECULAR IMMUNOLOGY (2009)
Patenting antibodies in Europe
Louise Holliday
MABS (2009)
Guardians at the gate Patent protection for therapeutic monoclonal antibodies-part 1
Kevin W. McCabe
MABS (2009)
Non-human primate immune libraries combined with germline humanization An (almost) new, and powerful approach for the isolation of therapeutic antibodies
Thibaut Pelat et al.
MABS (2009)
Development trends for therapeutic antibody fragments
Aaron L. Nelson et al.
NATURE BIOTECHNOLOGY (2009)
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Aran F. Labrijn et al.
NATURE BIOTECHNOLOGY (2009)
Gearing up for follow-on biologics
Bethan Hughes
NATURE REVIEWS DRUG DISCOVERY (2009)
IMGT (R), the international ImMunoGeneTics information system (R)
Marie-Paule Lefranc et al.
NUCLEIC ACIDS RESEARCH (2009)
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
Rafael Ponce et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Damian C. Ekiert et al.
SCIENCE (2009)
PEGYLATION FOR IMPROVING THE EFFECTIVENESS OF THERAPEUTIC BIOMOLECULES
Gianfranco Pasut et al.
DRUGS OF TODAY (2009)
RILONACEPT IN THE TREATMENT OF CHRONIC INFLAMMATORY DISORDERS
Michael F. McDermott
DRUGS OF TODAY (2009)
Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry
Charlotte Hagman et al.
ANALYTICAL CHEMISTRY (2008)
Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry
Olivier Heudi et al.
ANALYTICAL CHEMISTRY (2008)
Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum
Mathieu Dubois et al.
ANALYTICAL CHEMISTRY (2008)
Novel human antibody therapeutics: The age of the Umabs
Sigrid R. Ruuls et al.
Biotechnology Journal (2008)
A human anti-D monoclonal antibody selected for enhanced Fc gamma RIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies
Roland Beliard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
Christophe de Romeuf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities
Akito Natsume et al.
CANCER RESEARCH (2008)
When binding is enough: nonactivating antibody formats
Aran F. Labrijn et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
T. Shantha Raju
CURRENT OPINION IN IMMUNOLOGY (2008)
Considerations for the development of therapeutic monoclonal antibodies
Patrick G. Swann et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Editorial: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic
A. Beck et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
T. Wurch et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Monoclonal Antibodies - Regulatory Challenges
Christian K. Schneider
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Michel Chartrain et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Monoclonal Antibodies as Innovative Therapeutics
Janice M. Reichert
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins
Alain Beck et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
J. Vlasak et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
DARPins: A new generation of protein therapeutics
Michael T. Stumpp et al.
DRUG DISCOVERY TODAY (2008)
Human IgG2 antibodies display disulfide-mediated structural isoforms
Jette Wypych et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass
Thomas M. Dillon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The way forward, enhanced characterization of therapeutic antibody glycosylation: Comparison of three level mass spectrometry-based strategies
Elsa Wagner-Rousset et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Germline Humanization of a Non-human Primate Antibody that Neutralizes the Anthrax Toxin, by in Vitro and in Silico Engineering
Thibaut Pelat et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
Jordi Rodon et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Toward biosimilar monoclonal antibodies
Christian K. Schneider et al.
NATURE BIOTECHNOLOGY (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Economic issues with follow-on protein products
Michael Lanthier et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells
Mark Throsby et al.
PLOS ONE (2008)
Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function
Quin Zhou et al.
BIOTECHNOLOGY AND BIOENGINEERING (2008)
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange
Marijn van der Neut Kolfschoten et al.
SCIENCE (2007)
Affilin-novel binding molecules based on human γ-B-crystallin, an all 13-sheet protein
Hilmar Ebersbach et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor
Lynda Schneider et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties
Dragan Grabulovski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Insulin-like growth factor-I receptor signaling blockade combined with radiation
Gregory W. Allen et al.
CANCER RESEARCH (2007)
Optimization of humanized IgGs in glycoengineered Pichia pastoris
HJ Li et al.
NATURE BIOTECHNOLOGY (2006)
The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema
Jerrold H. Levy et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Immunotherapy of malignant ascites with trifunctional antibodies
MM Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
PEGylation, successful approach to drug delivery
FM Veronese et al.
DRUG DISCOVERY TODAY (2005)
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages
LE Harrington et al.
NATURE IMMUNOLOGY (2005)
Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NSO cells
A Beck et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
From rodent reagents to human therapeutics using antibody guided selection
J Osbourn et al.
METHODS (2005)
Nanobodies as novel agents for cancer therapy
H Revets et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies
KL Armour et al.
MOLECULAR IMMUNOLOGY (2003)
Cytokine traps: multi-component, high-affinity blockers of cytokine action
AN Economides et al.
NATURE MEDICINE (2003)
Domain antibodies: proteins for therapy
LJ Holt et al.
TRENDS IN BIOTECHNOLOGY (2003)
Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor
A Koide et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)